Acute liver injury associated with the use of ebrotidine, a new H2- receptor antagonist

Journal of Hepatology

Volumn 31, Issue 4, 1999, Pages 641-646

  Andrade, Raúl J ^h   Lucena, M Isabel ^a   Martin Vivaldi, Rafael ^c   Fernandez, M Carmen ^b   Nogueras, Flor ^c   Pelaez, Gloria ⁱ   Gomez Outes, Antonio ^a   Garcia Escaño, M Dolores ⁱ   Bellot, Vicente ^d   Hervás, Antonio ^e   Cárdenas, Francisco ^f   Bermudez, Francisco ⁱ   Romero, Manuel ^g   Salmerón, Javier ^d  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL TORRECÁRDENAS   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f Hospital General Basico   (Spain)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h Department of Clinical Pharmacology   (Spain)

ⁱ NONE

Author keywords

Acute liver injury; Ebrotidine; H2 receptor antagonist; Hepatotoxicity

Indexed keywords

AMINOTRANSFERASE; EBROTIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER INJURY; LIVER TOXICITY; MALE; PRIORITY JOURNAL;

EID: 0032831519     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80343-2     Document Type: Article

References (23)

1. Lewis JH. Hepatic effects of drugs used in the treatment of peptic ulcer disease. Am J Gastroenterol. 82:1987;987-1003.
2. Patel SS, Wilde MI. Ebrotidine. Drugs. 51:1996;974-980.
3. Romero A, Grau MT, Villamayor F, Sacristan A, Ortiz JA. Chronic toxicity of ebrotidine in rats and dogs. Arzneimittelforsch. 47:(Suppl 4A):1997;498-504.
4. Romero A, Rives A, Grau MT, Villamayor F, Sacristan A, Ortiz JA. Carcinogenicity studies on ebrotidine. Arzneimittelforsch. 47:(Suppl 4A):1997;515-519.
5. Farre M, Roset PN, Badenas JM, Ugena B, Marquez M, Albet C, et al. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses. Arzneimittelforsch. 47:1997;528-530.
6. Anonymous. Ebrotidine may combine antisecretory and gastroprotective properties. Drugs Ther Perspect. 8:1996;4-5.
7. Andrade RJ, Lucena MI, Perez-Moreno JM, Fernandez MC, Martin-Vivaldi R, Ramos Lara M, et al. Drug-induced hepatotoxicity: preliminary reults from a surveillance program in South Spain. J Hepatol. 26:(suppl 1):1997;297.
8. Report of an International Consensus Meeting. Criteria of druginduced liver disorders. J Hepatol. 11:1990;272-276.
9. Anonimo. Retirada de la Ebrotidina por su posible asociación a casos de hepatitis grave. Alerta de Farmacovigilancia. 18:1998;1-4.
10. Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 154:1994;311-316.
11. Bort R, Ponsoda X, Jover R, Gomez-Lechon MJ, Castell JV. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther. 288:1999;65-72.
12. Reddy RK, Brillant P, Schiff ER. Schiff ER Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology. 96:1989;1135-1141.
13. Zimmerman HJ. Acetaminophen poisoning and NSAID toxicity. Liver injury update: clinical implications and mechanism role of cells of the liver. AASLD Postgraduate Course. 1997;49-62.
14. Biour M, Poupon R, Grange JD, Chazouilleres O, Levy VG, Bodin F, et al. Hépatotoxicité des médicaments. Gastroenterol Clin Biol. 20:1996;744-779.
15. Zimmerman HJ. Hepatotoxicity. Dis Month. 39:1993;675-787.
16. Farrel GC. Drug-induced Liver Disease. 1994;Churchill, London.
17. García Rodríguez LA, Wallander MA, Stricker BHCh. The risk of acute liver injury associated with cimetidine and other acidsuppressing anti-ulcer drugs. Br J Clin Pharmacol. 43:1997;183-188.
18. Rush GF, Ripple M, Chenery R. Mechanism of oxmetidine (SKαF 92994) cytotoxicity in isolated rat hepatocytes. J Pharmacol Exp Ther. 233:1985;741-746.
19. 2)-receptor antagonists. Am J Med. 83:(Suppl 6A):1987;68-75.
20. García Rodríguez LA, Ruigómez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy. 17:1997;721-728.
21. Black M, Scott WE, Kanter R. Possible ranitidine hepatotoxicity. Ann Intern Med. 101:1984;203-210.
22. Gasbarrini G, Gentiloni N, Febbraro S, Gasbarrini A, Di Campli C, Cesana M, et al. Acute liver injury related to the use of niperotidine. J Hepatol. 27:1997;583-586.
23. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 58:1995;108-117.